OBJECTIVE: To evaluate the plasma profile of biomarkers potentially involved in AKI development following CPB.
METHODS: In a nested case-control study, plasma levels of 27 biomarkers in 11 AKI cases were compared with 25 controls.
RESULTS: Pre-CPB, plasma levels of epidermal growth factor and macrophage inflammatory protein-1beta, 2 h following CPB, soluble vascular cell adhesion molecule-1 (sVCAM-1), fractalkine and macrophage inflammatory protein-1alpha, and at later time points, sVCAM-1 and interleukin-6 were associated with AKI.
CONCLUSIONS: Biomarkers associated with AKI following CPB may merit further study.